Skip to content
value.today

OG DNA Genetics Inc.

Formerly 1171843 B.C. Ltd.

Total raised
$36 M
2 rounds on record
Latest round
$24 M
Nov 2018
First round on record
Oct 2018
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of OG DNA Genetics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2018$24 MNo. 2$10 to $50 million

OG DNA Genetics Inc.: Raise no. 2, Nov 2018

Investors in this round

38 investors had bought by the notice of Dec 7, 2018: 38 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$24 M of $24 M offered
Smallest investment taken
no minimum stated
What was sold
equity, other: Common Shares
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,489,400
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in British Columbia, Canada

People named in the notice

  • Charles Phillips · Executive Officer, Director · Chief Executive Officer
  • Donald Wayne Morris · Executive Officer, Director · Founder
  • Israel Aaron Yarkoni · Executive Officer · Founder
  • Joshua Aaron Hamlin · Executive Officer · Chief Legal Officer
  • Rezwan Aaron Khan · Executive Officer · Director of Business Development

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • KES 7 Capital Inc. · Toronto, Ontario, CanadaSold in no state named, and outside the US

Remarks in the notice

  • On fees: “Commissions of $1,391,700 plus fees of $47,700 and expenses of $50,000, totaling $1,489,400, paid solely in connection with distributions outside of U.S.”

Signed by Charles Phillips, Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 7, 2018. Read the notice at the SEC.

equitySEC
Oct 2018$12 MNo. 1$10 to $50 million

OG DNA Genetics Inc.: Raise no. 1, Oct 2018

Investors in this round

50 investors had bought by the notice of Nov 14, 2018: 50 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$12 M of $24 M offered; $12 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, other: Subscription Receipts and Common Shares
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$726,040
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in British Columbia, Canada

People named in the notice

  • Charles Phillips · Executive Officer, Director · Secretary
  • Donald Morris · Executive Officer, Director · President

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • KES 7 Capital Inc. · Toronto, Ontario, CanadaSold in no state named, and outside the US

Remarks in the notice

  • On fees: “Commissions of $626,040 plus expenses of $100,000, totaling $726,040, paid solely in connection with distributions outside of U.S.”

Signed by Charles Phillips, Secretary. Source: SEC Form D, newest notice filed Nov 14, 2018. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • OG DNA Genetics Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2018).

    SEC Form D · Dec 2018

  • The industry group it chose in its notices: Other.

    SEC Form D · Dec 2018

That is all the official record says: OG DNA Genetics Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of OG DNA Genetics Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 50 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by OG DNA Genetics Inc.
NameRoleNamed in
Charles PhillipsChief Executive OfficerDec 2018
Donald Wayne MorrisFounderDec 2018
Israel Aaron YarkoniFounderDec 2018
Joshua Aaron HamlinChief Legal OfficerDec 2018
Rezwan Aaron KhanDirector of Business DevelopmentDec 2018
Donald MorrisPresidentNov 2018
Charles PhillipsChief Executive OfficerDec 2018
Donald Wayne MorrisFounderDec 2018
Donald MorrisPresidentNov 2018